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Toll like receptors are expressed primarily by immune cells and are known to 
be part of the innate immune system. In the past decade involvement of TLRs 
in several physiologic and pathologic pathways has been proved. Pain 
transmission via glial activation is one of such interesting fields. Both 
pathological pain states and treatment have also been shown to be related to 
TLR-related pathways. Opioid agonists are found to possess TLR4 agonistic 
effects and glial activity. Targeting TLRs could be a novel method for 
treatment of neuropathic pain. Moreover attenuation of glial activation by the 
aim of selective TLR antagonistic drugs, may become a preferred way of 
separating the beneficial (analgesia) and unwanted effects of opioids, 
improving their safety and efficacy. 
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What are TLRs 
Toll like receptors (TLRs) are a class of 
proteins that are among key elements of innate 
immunology structure; so, they are seen in dendritic 
cells, macrophages, neutrophls, mucosal epithelial 
cells, and other cells of innate immunology. General 
understanding of the immune system is based on that 
“self and foreign” must be distinguished so self 
paricles are tolerated and the aliens can be defeated. 
Triggering innate or adaptive immune responses and 
recognition of foreign antigens are processed through 
several pathways. Innate immunity involves binding 
of the pathogen by so-called pattern recognition 
receptors (PRR) to enablefurther danger signaling  
(1).Within the PRR, the toll like receptor family is 
specifically involved in immune cell activation. Toll 
like receptors (TLRs) are pattern recognition 
receptors, which means they recognize PAMPs 
(Pathogen-Associated Molecular Patterns) and 
DAMPs ( Damage-Associated Molecular Patterns) 
from tolerable self antigens.Whenever a pathogenic 
molecule traspasses the physiologic barriers and 
enters body environment, it will be encountered wih 
TLRs, which then activate the innate immune system. 
(2-4) Interestingly, TLRs also recognize endogenous 
ligands on the injured cells or over the surface of 
tissue fragments, representing endogenous danger 
signals. Each type pf TLRs binds to several specific 
ligands, and so a more specialized pathway will be 
activated through each (5). 
TLRs are recognized from TLR1 to TLR13; 
however, TLR1 to TLR11 are distinguished in human 
being  (6). TLR1 is a known receptor for Bacterial 
products such as tri-acyl lipopeptides,while TLR 2 
recognizes gram positive bacterial products and 
several viral proteins (7). TLR3 only recognizes Viral 
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double-stranded RNA,wheras TLR9 is able to detect 
both viral and bacterial DNA  (8). TLR4 is mainly 
known for detecting endotoxin (lipopolysaccharyde or 
LPS), but it also recognizes host cell stress and 
damage products like cytoplasmin and/or nuclear 
particles like DNA,RNA and heat shock proteins. 
Extracellular matrix breakdown products such as 
hyaluronan, heparan sulfate, fibrinogen, or the 
fibronectin end products can also activate TLR4. (1, 
9). 
TLR4 
LPS can cause endotoxic shock by inducing the 
release of proinflammatory cytokines and chemokines 
from immune and non-immune cells. In humans, 
TLR4 mutations are also associated with impaired 
responsiveness to LPS It was recently suggested that 
endogenous ligands have shown to activate NFκB 
mobilization and mitogen-activated protein kinases 
(MAPK) pathways through their direct binding to 
TLR4. TLR4 recognizes endogenous molecules that 
are exposed during cellular injury and extracellular 
matrix remodeling, which means that TLR4 signaling 
may also be involved in activation of immune 
responses during independent of pathogen invasion. 
TLRs and Pain 
Pain processing is a dynamic chain of events, 
controlled by regulatory modulators. Under normal 
conditions, a painful stimulus is perceived via 
activation of “pain”-receptive sensory nerve fibers., 
also known as “nociceptors”. The resultant action 
potentials conduct the information of potential or 
actual tissue injury through pain transmission neurons 
in the spinal cord dorsal horn. These neurons send the 
information to multiple sites within the brain where 
various aspects of the pain experience (sensation, 
analysis of meaning, emotional reactions, etc) are 
analyzed and responded to. Pain messages can be 
suppressed by drugs like morphine, transferred 
unaltered, or amplified under several pathologic 
conditions. When pathologic pain develops as a result 
of peripheral nerve injury, it have been attributed to a 
variety of neuronal changes, including altered 
excitability of sensory neurons, alterations in which 
neurotransmitters are synthesized and released by 
various sensory neurons, alterations in pain 
transmission neuron excitability via multiple changes 
in receptor and ion channel functions, etc. Several 
mechanisms are known in pain transmission and 
sensitization/inhibition (4). 
Acute pain is transient and mostly resolves 
within weeks, while persistent pain can last for up to 
3 to 6 months.  (10) Both acute and persistent pain 
arise from tissue damage and/ or inflammation, and so 
the nociceptive transmission in these cases is not 
necessarily dysfunctional. Several well- identified 
signals trigger pain conduction following any painfol 
stimulant. Substance P which binds to the neurokinin 
1 receptor (also excitatory amino acid glutamate, 
binding to AmPA (α-amino-3-hydroxy-5-methyl-4-
isoxazole proprionic acid) and NMDA (N-methyl-d-
aspartate) receptors, calcitonin gene-related peptide 
(CGRP), galanin, vasoactive intestinal polypeptide 
and somatostatin, are some of well-known chemical 
signals  (11, 12). The activity of these pain-projection 
neurons is also influenced by local inhibitory 
interneurons in the spinal cord and by supraspinal 
mechanisms (4). 
Although acute pain from an identifiable 
trauma is considered a symptom of tissue injury or 
disease, chronic and recurrent pain is a disease. Under 
normal conditions pain pathway is activated to induce 
protective responses which help to prevent further 
tissue damage. Treating clearly identifiable causes of 
pain normally leads to a resolution of such pain. 
When injury or inflammation is prolonged, ongoing 
excitation of nociceptive neurons results in chronic 
pain. Injured or inflamed tissue in the CNS can also 
sensitize neurons in the spinal cord, leading to chronic 
pain  (4). These chemical and neural changes occur at 
the site of tissue injury in the body, either at the nerve 
endings of pain fibres or along their axons, and at 
first-order synapses, both pre- and postsynaptically in 
the dorsal horn of the spinal cord and/or in supra-
spinal pain-processing areas. These well-
characterized changes in neuronal and biochemical 
processing, from normal conditions to a pain-
facilitatory state in the dorsal horn of the spinal cord, 
are collectively known as “central sensitization”  (13). 
Several mechanisms that bring about central 
sensitization have been described
.
 The best 
characterized involves a change in the function of 
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neuronal NMDA (N-methyl-d-aspartate) receptors in 
the spinal cord dorsal horn  (14). Chronic Pain is 
mediated by several neuronal and immune pahways. 
The interaction between neuronal and immune system 
in the CNS is known as “Central Immune 
Signaling”.TLRs are the critical part of this signaling 
process, enhancig neuroexcitation via 
proinflammatory mediator release (2, 15). 
TLR and glial activation 
Altered activity of primary sensory nociceptors 
and/or spinal and/or brain neurons relevant to the pain 
pathway, leads to chronic neuropathic pain. 
Neuropathic pain is often associated with direct 
trauma or inflammation of peripheral nerves  (16). 
Neuropathic pain initiates by sensory neuron injury, 
which activates spinal cord glia. Glial cells are 
important mediators in the pathological pain process. 
Although glia are well known for having a number of 
nurturing functions that are necessary for healthy 
neuronal communication, on strong activation they 
act as immunoresponsive cells or exert a 
neuroprotective effect. Glia can contribute to 
neuropathic-pain processing by releasing a number of 
glial and neuronal signalling molecules. Neuropathic 
pain is a fine example of glia roles in astrocytic 
activation  (4). 
Activation signaling is tought to be mostly 
started by TLR4 stimulatation, which then contributes 
in CNS immune sysem activation and 
proinflammatory cytokines release (2, 17, 18). TLR4 
is expressed on the surface of glia but not on the 
neurons (19). It also has been demonstrated that 
mRNA for TLR4 in spinal cord is increased after L5 
nerve transection (20).The activation of TLR2 and 
TLR4 induces the release of IL-1β, TNFα and IL-6, 
that leads to an excitatory positive feedback loop in 
pain pathway (21). Microglia are the first glial type to 
become activated and that their activation leads in 
turn to the recruitment of nearby astrocytes, so both 
cell types contribute to observed alterations in pain 
(22). astrocytes and microglia interact. Their released 
products can synergize, and substances released by 
one can activate the other. Regarding synergy, 
 
Figure 1.  TLR4-mediated Neuronal Excitability. Several contributors like painful stimuli, exogenous 
materials ( bacterial lipopolysaccharides), endogenous danger signals of cellular stress or damage (Alarmins), 
and also release of DNA and other self substances ( normally hidden from immune system) will activate glia 
through their interaction with Toll like receptors. As a result glial cells secret several “neuroexcitatory pain 
enhancing substances”,shown in the arrow.These mediators will initiate and augment neuronal excitation 
through several mechanisms (i.e. NMDA and AMPA receptor upregulation, GABA receptor downregulation, 
potassium outward current attenuation and sodium inward current enhancment). 
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proinflammatory cytokines can synergize with each 
other as well as with neurotransmitters and 
neuromodulators (23).Searching for the role of TLR4 
in neuropathic pain development and treatment, it has 
also been observed that tricyclic compounds such as 
amitryptiline,commonly used in neuropathic pain 
management, has obvious TLR4 inhibitory activity 
while enhancing opiod analgesic effects (24). 
TLRs and Opioids 
Opioids have recently been shown to activate 
glia through a receptor that is distinct from the 
classical opioid receptor on neurons. This opioid-
induced activation of glia induces them to release pro-
inflammatory cytokines, which further suppresses 
opioid analgesia. Repeated exposure to opioids leads 
to enhanced pro-inflammatory cytokine release from 
glia. (25) Opioids not only suppress pain, they also 
activate endogenous counter-regulatory mechanisms 
that, for example, actively oppose opioid-induced 
pain suppression, enhance analgesic tolerance 
wherein repeated opioids lose their ability to suppress 
pain, and enhance dependence wherein organisms 
require continued opioid exposure to stave off drug 
withdrawal. (26) These modulatory controls have 
again been attributed to a variety if neuronal 
mechanisms, including release of endogenous anti-
opioid peptides such as cholecystokinin, 
internalization and/or desensitization of opioid 
receptors, alterations in opioid receptor signaling 
cascades, and so on
.
Activation of TLR4 leads to 
downstream releae of inflammatory modulators 
including TNF-α and interleukin-1.Constantant low-
level release of these modulators is thought to reduce 
the efficacy of opioid drug treatment with time, 
resulting in development of tolerance to opioid 
analgesic effects (27). 
Side effects of extended opioid usage,and its 
known phnomena known as “hyperalgesia” and 
“allodynia”, may also be related to constatnt 
inflammatory mediators releae (28). Blockade of 
TNF-α and interleukin-1 actions is known to enhance 
the analgesic effects of opioid analgesics, and also to 
reduce the development of tolerance to them.The 
same results have been demonstrated wih drugs 
blocking TLR4.  
Blocking TLR-dependent opioid-induced glial 
 
Figure 2.  Non-Stereoselectivity of Toll like receptors for opioid agonists/antagonists. Classic opioid 
receptors expressed by neurons are highly stereoselective for binding (-)opioid isomers, while TLR4 
(expressed predominantly on microglia) binds to both (+) and (-) isomers. This fact predicts that neuronally 
inactive (+)-opioid antagonists such as (+)-naloxone and (+)-naltrexone could be developed into clinically 
viable drugs for potentiating opioid analgesia and without altering analgesic effects. 
Sezari                                                                                                      The role of Toll-like receptors in pain control 
 Journal of Cellular & Molecular Anesthesia (JCMA) 
28 
activation enhances acute opioid analgesia and 
suppresses the development of opioid tolerance. 
Furthermore, suppressing glial activation suppresses 
the development of opioid dependence and 
withdrawal, suppresses opioid reward linked to drug 
abuse and suppresses other negative side effects, such 
as respiratory depression. Preventing glial activation 
in response to opioids represents a promising way to 
enhance the clinical efficacy of opioid drugs while 
decreasing their unwanted effects. It has been 
observed that inhibition of intratechal TLR4 by its 
antagonists enhances opoid anlgesia and suppresses 
neuropathic pain formation and decreses its severity 
(17). TLR4 is also importantly involved in glial 
dysregulation of opioid actions. Those studies 
demonstrate that, similarly to neuropathic pain, 
morphine upregulates TLR4 expression in microglia 
(29). Activation of glial TLR4 by opiod agonists 
triggers release of several cytokines and 
neurotransmitters, resembling inflammation state,and 
results in further opioid receptor tolerance. IL-1 and 
other proinflammatory cytokines oppose the ability of 
morphine to suppress pain, showing a round-way 
relationship between opioids and TLR pathway (30). 
TLR4 has also been shown to be involved in 
the long-term side effects of opioid analgesic 
drugs.Various ligands of µ-opioid receptor has been 
tested and found to also possess agonistic and/or 
antagonistic effects on TLR4, with opioid agonists 
such as morphine being TLR4 agonists,while opioid 
antagonists such as naloxone were found to be 
antagonists of TLR4 (Figure 2). Taken together with 
the fact that neuropathic pain is created, at least in 
part, via activation of TLR4 contributing to microglial 
activation (17, 20), these data suggest that TLR4 may 
prove to be a target worth exploring for improving 
clinical pain control. Hutchinson et al. have shown 
these effects in several studies (17, 31, 32). 
Intrathecal administration of either the TLR4 receptor 
antagonist or intrathecal morphine produce analgesia  
(29). Considerably, several clinically relevant opioids 
including morphine, methadone, meperidine, and 
fentanyl are observed to activate TLR4 (29). 
Clinical Implications 
Recent discoveries in the role of the immune 
system in pathological pain states, including 
neuropathic pain could be a potential breakdown. 
Within the few past years, recognition of immune-like 
glial cells and their relation with the efficacy of 
opioids for pain control has been observed in animal 
models (32). 
The potential implications of TLR4 in pain 
management are also vast. Many of the present 
possible treatments for pathologic pain are 
unsatisfactory. Most of pain treating drugs currently 
used target neurons. The discovery of glial regulatory 
role through TLR-dependent mechanisms is bringing 
up a whole new perspective in pain management 
strategies.  
Glial TLR4 modulatory, impacts on the 
therapeutic effects of opioids has not yet been 
assessed in human. The fact that non-µ opioid 
receptors (TLRs) appear to mediate the glial 
activating effects of opioids suggests that the clinical 
efficacy of these analgesics can be improved in 
magnitude and duration by separating the glial 
activating effects of opioids from their pain 
suppressive ones. Also, dependence and withdrawal 
are unwanted consequence of opioid use which can 
occur in humans after even brief opioid use  (33, 34). 
Coadministration of a “glial activation inhibitor” with 
an opioid might be a probable way to intensify 
analgesia, delay the development of tolerance, and 
decrease the incidence of opioid dependence or 
withdrawal. 
Conclusion 
As surgical procedures are growingin numbers 
worldwide, anesthesia techniques and drugs will 
evolve. Searching for more effective drugs with less 
side effects, TLR agonist/antagonists could have new 
role in modern anesthesia, both by their own 
specificities and their synergistic effects on other 
well-known analgesic drugs. Further studies can help 
us to learn more about their effects on other 
physiologic processes within body throughout 
anesthesia and surgery. 
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